Thiogenesis Therapeutics, Corp. TTIPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.08% | 18.81% | 18.31% | 43.22% | 30.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.38% | 67.40% | 103.69% | 55.10% | 6.11% |
| Operating Income | -25.38% | -67.40% | -103.69% | -55.10% | -6.11% |
| Income Before Tax | -29.41% | -82.50% | -132.74% | -62.68% | -9.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.41% | -82.50% | -132.74% | -62.68% | -9.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.41% | -82.50% | -132.74% | -62.68% | -9.99% |
| EBIT | -25.38% | -67.40% | -103.69% | -55.10% | -6.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.51% | -67.89% | -116.83% | -45.35% | 1.74% |
| Normalized Basic EPS | -13.54% | -68.27% | -117.46% | -45.60% | 1.59% |
| EPS Diluted | -13.51% | -67.89% | -116.83% | -45.35% | 1.74% |
| Normalized Diluted EPS | -13.54% | -68.27% | -117.46% | -45.60% | 1.59% |
| Average Basic Shares Outstanding | 15.27% | 9.48% | 7.09% | 7.15% | 8.65% |
| Average Diluted Shares Outstanding | 15.27% | 9.48% | 7.09% | 7.15% | 8.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |